Hanmi Pharmaceutical | Sustainability Performance
Research-driven pharmaceutical company producing prescription drugs and health products
1973
South Korea
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#2546
Overallⓘ#24
in South Koreaⓘ#58
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Health and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Critical
Aligned
Intensity
Water consumption intensity (m³ /$M)
Industry Benchmark
355.7
B/M 131.1
Powered by illuminem and GIST Impact
Controversy level
- Hanmi Pharmaceutical Co Ltd, Korean major pharma (Lim family), has faced sustained Korean FSC enforcement scrutiny including the historic 2016 Boehringer Ingelheim USD 730 million BI-1482694 olmutinib licensing collapse share price shock, plus the contested 2024 sustained Lim family-OCI controlling shareholder governance dispute affecting Korean institutional minority shareholders.
